Skip Nav Destination

Issue Archive

Select Decade

Select Year

Issue

Volume 133, Issue 16

April 18 2019

In this Issue

BLOOD COMMENTARIES
SPECIAL REPORT
BLOOD SPOTLIGHT
CLINICAL TRIALS AND OBSERVATIONS
HEMATOPOIESIS AND STEM CELLS
LYMPHOID NEOPLASIA
MYELOID NEOPLASIA
PLATELETS AND THROMBOPOIESIS
BLOOD WORK
RETRACTION
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS

Storming the Castle with TCP
Clinical Trials & Observations

Frits van Rhee,Katie Stone

View Articletitled, Storming the Castle with TCP

Hematopoiesis and Stem Cells

Context-specific tumor suppression by PHF6

Jennifer J. Trowbridge

View Articletitled, Context-specific tumor suppression by PHF6

PLATELETS AND THROMBOPOIESIS

α_IIbβ₃ changes gears in MKs and platelets

Naoshi Sugimoto,Koji Eto

View Articletitled, αIIbβ3 changes gears in MKs and platelets

SPECIAL REPORT

The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
CME

Rein Willemze,Lorenzo Cerroni,Werner Kempf,Emilio Berti,Fabio Facchetti,Steven H. Swerdlow,Elaine S. Jaffe

View Articletitled, The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas

BLOOD SPOTLIGHT

Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL
Clinical Trials & Observations

Emily Curran,Wendy Stock

View Articletitled, Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL

CLINICAL TRIALS AND OBSERVATIONS

Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease
Clinical Trials & Observations

Lu Zhang,Ai-lin Zhao,Ming-hui Duan,Zhi-yuan Li,Xin-xin Cao,Jun Feng,Dao-bin Zhou,Ding-rong Zhong,David C. Fajgenbaum,Jian Li

View Articletitled, Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease

HEMATOPOIESIS AND STEM CELLS

PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia

Helen M. McRae,Alexandra L. Garnham,Yifang Hu,Matthew T. Witkowski,Mark A. Corbett,Mathew P. Dixon,Rose E. May,Bilal N. Sheikh,William Chiang,Andrew J. Kueh,Tan A. Nguyen,Kevin Man,Renee Gloury,Brandon J. Aubrey,Antonia Policheni,Ladina Di Rago,Warren S. Alexander,Daniel H. D. Gray,Andreas Strasser,Edwin D. Hawkins,Stephen Wilcox,Jozef Gécz,Axel Kallies,Matthew P. McCormack,Gordon K. Smyth,Anne K. Voss,Tim Thomas

View Articletitled, PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia

Supplemental data

LYMPHOID NEOPLASIA

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Andres Forero-Torres,Radhakrishnan Ramchandren,Abdulraheem Yacoub,Michael S. Wertheim,William J. Edenfield,Paolo Caimi,Martin Gutierrez,Luke Akard,Carolina Escobar,Justin Call,Daniel Persky,Swaminathan Iyer,Douglas J. DeMarini,Li Zhou,Xuejun Chen,Fitzroy Dawkins,Tycel J. Phillips

View Articletitled, Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Supplemental data

Viral, immunologic, and clinical features of primary effusion lymphoma
Clinical Trials & Observations

Kathryn Lurain,Mark N. Polizzotto,Karen Aleman,Manisha Bhutani,Kathleen M. Wyvill,Priscila H. Gonçalves,Ramya Ramaswami,Vickie Ann Marshall,Wendell Miley,Seth M. Steinberg,Richard F. Little,Wyndham Wilson,Armando C. Filie,Stefania Pittaluga,Elaine S. Jaffe,Denise Whitby,Robert Yarchoan,Thomas S. Uldrick

View Articletitled, Viral, immunologic, and clinical features of primary effusion lymphoma

Reproduced with permission from the Cleveland Clinic Foundation (CCF).

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Clinical Trials & Observations Brief Report

Eric D. Hsi,Hongli Li,Andrew B. Nixon,Heiko Schöder,Nancy L. Bartlett,Michael LeBlanc,Sonali Smith,Brad S. Kahl,John P. Leonard,Andrew M. Evens,David W. Scott,Lisa M. Rimsza,Jonathan W. Friedberg

View Articletitled, Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study

Supplemental data

MYELOID NEOPLASIA

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations

Jonas Samuel Jutzi,Titiksha Basu,Maximilian Pellmann,Sandra Kaiser,Doris Steinemann,Mathijs A. Sanders,Adil S. A. Hinai,Annelieke Zeilemaker,Sarolta Bojtine Kovacs,Christoph Koellerer,Jenny Ostendorp,Konrad Aumann,Wei Wang,Emmanuel Raffoux,Bruno Cassinat,Lars Bullinger,Brigitte Schlegelberger,Peter J. M. Valk,Heike Luise Pahl

View Articletitled, Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations

Supplemental data

PLATELETS AND THROMBOPOIESIS

Disrupted filamin A/α_IIbβ₃ interaction induces macrothrombocytopenia by increasing RhoA activity

Alessandro Donada,Nathalie Balayn,Dominika Sliwa,Larissa Lordier,Valentina Ceglia,Francesco Baschieri,Cyril Goizet,Rémi Favier,Lucie Tosca,Gérard Tachdjian,Cecile V. Denis,Isabelle Plo,William Vainchenker,Najet Debili,Jean-Philippe Rosa,Marijke Bryckaert,Hana Raslova

View Articletitled, Disrupted filamin A/αIIbβ3 interaction induces macrothrombocytopenia by increasing RhoA activity

Supplemental data

BLOOD WORK

Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion

Adriana Plesa,Pierre Sujobert

View Articletitled, Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion

RETRACTION

Nankanja R, Kiyaga C, Geisberg M, Serrao E, Balyegyusa S. Implementation of a sickle cell disease screening initiative in Uganda with HemoTypeSC™ [abstract]. Blood. 2018;132(suppl 1). Abstract LBA-3.

View Articletitled, Nankanja R, Kiyaga C, Geisberg M, Serrao E, Balyegyusa S. Implementation of a sickle cell disease screening initiative in Uganda with HemoTypeSC™ [abstract]. Blood. 2018;132(suppl 1). Abstract LBA-3.

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

2018 WHO-EORTC classification update
CME

View Articletitled, 2018 WHO-EORTC classification update

Cover Image

Cover Image

Immunofluorescence micrograph of a human megakaryocyte derived from a filamin A–mutated induced pluripotent cell line on fibrinogen. The presence of large stress fibers (green) results from the abnormal activity of the small GTPase RhoA caused by the absence of the filamin A protein. See the article by Donada et al on page 1778.
Front Matter
Table of Contents
Back Matter
Editorial Board

All Issues

Advertisement intended for health care professionals

Email alerts

First Edition Alert

Latest Issue Alert

Latest
Most Read
Most Cited

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia

Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads

Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia

Leukemic myeloblasts with erythrophagocytosis

Advertisement intended for health care professionals

Table of Contents

BLOOD COMMENTARIES

Storming the Castle with TCP
Clinical Trials & Observations

Context-specific tumor suppression by PHF6

α_IIbβ₃ changes gears in MKs and platelets

SPECIAL REPORT

The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
CME

BLOOD SPOTLIGHT

Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL
Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease
Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia

LYMPHOID NEOPLASIA

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Viral, immunologic, and clinical features of primary effusion lymphoma
Clinical Trials & Observations

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Clinical Trials & Observations Brief Report

MYELOID NEOPLASIA

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations

PLATELETS AND THROMBOPOIESIS

Disrupted filamin A/α_IIbβ₃ interaction induces macrothrombocytopenia by increasing RhoA activity

BLOOD WORK

Cannibalistic acute myeloid leukemia with ZMYND11-MBTD1 fusion

RETRACTION

Nankanja R, Kiyaga C, Geisberg M, Serrao E, Balyegyusa S. Implementation of a sickle cell disease screening initiative in Uganda with HemoTypeSC™ [abstract]. Blood. 2018;132(suppl 1). Abstract LBA-3.

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

2018 WHO-EORTC classification update
CME

Email alerts

ASH Publications

American Society of Hematology

Issue Archive

Table of Contents

BLOOD COMMENTARIES

Storming the Castle with TCP Clinical Trials & Observations

SPECIAL REPORT

The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas CME

BLOOD SPOTLIGHT

Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL Clinical Trials & Observations

CLINICAL TRIALS AND OBSERVATIONS

Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease Clinical Trials & Observations

HEMATOPOIESIS AND STEM CELLS

LYMPHOID NEOPLASIA

Viral, immunologic, and clinical features of primary effusion lymphoma Clinical Trials & Observations

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study Clinical Trials & Observations Brief Report

MYELOID NEOPLASIA

PLATELETS AND THROMBOPOIESIS

BLOOD WORK

RETRACTION

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS

2018 WHO-EORTC classification update CME

Cover Image

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only

Storming the Castle with TCP
Clinical Trials & Observations

The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
CME

Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL
Clinical Trials & Observations

Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease
Clinical Trials & Observations

Viral, immunologic, and clinical features of primary effusion lymphoma
Clinical Trials & Observations

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study
Clinical Trials & Observations Brief Report

2018 WHO-EORTC classification update
CME